PECAM1 and non-small cell lung carcinoma: The expression of CD31, a sensitive and specific marker for vascular differentiation, was also down-regulated upon treatment, especially the combinational treatment (Figure 7F), indicating that the combination administration of lumbrokinase and bevacizumab could produce a more pronounced anti-tumor growth effect in the xenografts of NSCLC cells by inhibiting tumor angiogenesis and development.